查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1829114

免疫肿瘤学检测市场（按技术类型、产品、样本类型、最终用户、适应症和应用）—全球预测，2025-2032

Immuno Oncology Assays Market by Technology Type, Product, Sample Type, End User, Indication, Application - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年免疫肿瘤检测市场规模将成长至 231.6 亿美元，复合年增长率为 15.69%。

主要市场统计数据
基准年2024年 72.1亿美元
预计2025年 83.3亿美元
预测年份：2032年 231.6亿美元
复合年增长率（%） 15.69%

权威介绍，阐述免疫肿瘤学检测在研究、临床开发和诊断用例中的战略重要性和范围

免疫肿瘤学检测正处于快速发展的生物学理解和日益复杂的测量技术的交汇点。本介绍重点介绍了该领域当前的重点：提高检测灵敏度和特异性、整合多体学读数以及将实验室发现转化为临床可操作的工具。本报告还将分析影响开发和商业化路径的技术，包括技术发展、产品差异化、样本处理考量、最终用户采用模式以及应用主导的用例。

本节将揭示免疫肿瘤学检测为何在现代肿瘤学研究和治疗开发中占据核心地位。从早期生物标记发现到伴随诊断，再到临床试验中的免疫监测，检测方法都是客观决策的基石。报告始终强调可重复性、监管合规性和营运扩充性，这些因素决定了一项技术能否从探索性应用转向常规部署。引言部分概述了后续章节如何提供涵盖技术、商业性和区域层面的策略背景，以支持投资者、开发者和从业者的决策。

技术、监管和商业性变革的综合体将重塑检测方法的发展，并加速转化和临床应用

过去几年，免疫肿瘤学检测的科学和商业性格局发生了翻天覆地的变化。单细胞分辨率、多重蛋白质检测和高通量定序的进步，共同扩展了可测量免疫表型的范围。同时，曾经主要用作研究工具的平台，正透过改善自动化、标准化和品管，朝向临床级应用迈进。

同时，支持检测开发的生态系统也在改变。仪器製造商、试剂供应商和受託研究机构之间的伙伴关係正变得更加策略化和垂直整合。当侦测工作流程的设计考虑到最终使用者的限制（例如样本量有限、临床交付压力以及可互通资料输出的需求）时，这种趋势会加速。监管期望也在不断发展，要求开发人员在开发早期就证明分析的有效性、临床相关性和强大的品管系统。这些共同的变化创造了一个环境：如果新的检测方法要充分发挥其在研究和患者照护的潜力，技术创新必须与操作严谨性相匹配，并有明确的应用路径。

不断变化的关税动态如何推动供应链弹性、供应商多样化以及检测采购和製造的本地化策略

贸易政策的变化和关税调整，为营运全球供应链并向临床和研究实验室部署检测试剂的组织带来了额外的复杂性。关税波动会影响设备和耗材的筹资策略，影响供应商多元化、区域库存分期和在地化製造能力的决策。许多组织正在权衡跨境采购的营运成本与维持专用试剂和设备的战略价值，而这些试剂和设备可能只能从有限的全球供应商处获得。

作为应对，相关人员正在采取各种缓解措施。一些机构正在重新评估供应商合同，并签订长期协议以稳定价格和供应。另一些机构则加快替代供应商的资格审查流程，或投资本地製造合作伙伴和委託製造製造商，以降低关税导致的成本波动风险。此外，采购和供应链团队正在与研发和临床营运部门更紧密地合作，优先考虑关键零件，并设计出更少依赖单一供应商的检测方法。这些调整旨在保持研究和临床项目的连续性，同时在不断变化的贸易政策中保持合规性和成本效益。

详细的细分洞察揭示了技术平台、产品类型、样品类型、最终用户需求、适应症和应用之间的相互作用如何影响检测优先级

细分市场层面的动态揭示了创新、采用和商业性紧张局势在技术类型、产品类型、样本格式、最终用户需求、适应症和应用方面的交汇点。在技​​术领域，流式细胞技术等成熟技术与质谱流式细胞仪和次世代定序仪共存，各有优势。虽然传统流式细胞技术仍然是表型分析的主要手段，但频谱流式细胞技术扩展了多路復用能力，而质谱流式细胞仪能够进行高度参数分析，从而进行深度免疫表型分析。免疫测量形式不断发展，从传统的 ELISA 演变为多路復用免疫测量，从而提供更广泛的细胞激素组和更高的通量。次世代定序仪方法包括针对免疫相关基因座定制的靶向组、提供更广泛基因组图谱的全外EXOME组测序以及用于全面分析的全基因组测序，每一层都在深度、广度和成本之间取得平衡。

耗材包括探针、抗体、试剂和试剂套件，必须针对批间一致性和检测特异性进行最佳化。仪器包括支援高通量工作流程的自动化系统和基于平台的仪器，旨在灵活用于多种检测类型。基于血液的检测提供微创纵向监测，细胞株工作流程促进机制发现，基于组织的检测提供肿瘤微环境分析所必需的空间和背景资讯。最终用户的优先顺序各不相同：包括研究机构和大学在内的学术和研究机构优先考虑检测灵活性和新颖的读数；诊断实验室强调法规遵从性和通量；医院和诊所要求快速週转和临床效用；製药和生物技术公司优先考虑检测的可重复性和与临床试验工作流程的整合。乳癌、血液癌、肺癌和黑色素瘤的检测各自面临不同的组织可用性、生物标记特征和临床终点。按应用进行细分，例如生物标记发现、伴随诊断、细胞激素分析、免疫监测和肿瘤微环境分析，确定检测性能阈值和数据解释框架，并告知该方法是否最适合发现研究、诊断开发或临床试验。

综合考虑这些环节，我们发现，成功的检测策略需要将技术选择、产品设计和操作执行与特定的样本环境、最终用户工作流程和治疗适应症相结合。在检测标准化、跨平台数据协调和以用户为中心的自动化方面的过渡性投资，将弥补有前景的方法与广泛应用之间的差距。

区域比较洞察，展示美洲、欧洲、中东和非洲以及亚太地区的市场特征如何影响采用、检验和商业化策略

区域特征对检测方法的开发重点、商业化策略和合作有显着的影响。在美国，产学合作和成熟的临床试验基础设施支持新型检测方法快速推进至临床试验阶段，而美国的监管途径和报销机制则指导伴随诊断​​的设计和验证。该地区的创投和企业投资活动通常会加速平台技术的扩展，而靠近大型临床网路的优势则有利于开展广泛的临床检验计画。

欧洲、中东和非洲呈现出一种多元化的格局，协调一致的监管环境、跨境研究合作以及国家医疗保健体系既带来了机会，也带来了复杂性。欧洲研究中心经常主导以免疫分析和肿瘤微环境表征为重点的多中心研究，但开发人员必须考虑不同司法管辖区不同的监管预期和报销框架。在中东和非洲，对研究能力和临床基础设施的投资不断增长，正在催生对可在集中实验室进行的、可靠且可扩展的检测方法的新兴需求。

亚太地区正经历科学研究产出的快速成长、临床试验的增加以及对本地生产和产能建设的高度重视。一些国家正在优先发展生物技术和生命科学项目，培育支持检测创新以及试剂和设备本地生产的生态系统。该地区还提供了製定个人化诊断策略的机会，这些策略能够反映特定人群的疾病生物学和医疗保健服务模式。在整个地区，跨境合作和数数位资料共用工作正在加速方法标准化和最佳实践的传播。

主要企业层面动态，说明平台模组化、试剂品质、策略伙伴关係和服务模式如何塑造竞争优势和采用路径

产业参与者正透过结合专有检测化学方法、整合平台和服务导向模式来脱颖而出。同时，试剂和耗材供应商则专注于抗体验证、试剂稳定性和批次间一致性，以减少下游数据差异。受託研究机构和专业服务供应商正在成为缺乏内部能力进行大规模免疫监测或复杂组织检测的机构的策略合作伙伴，提供检测开发、样本处理和数据分析等一站式服务。

诊断公司与製药赞助商之间的合作正变得越来越普遍，这得益于伴随诊断对患者分层和支持治疗核准途径的需求。同时，规模较小的创新者正在利用高度多路復用的检测方法、先进的单细胞分析或针对特定临床工作流程的精简自动化技术开拓市场。跨部门伙伴关係，包括学术衍生公司和共同开发契约，在提高检测稳健性和加速临床验证方面发挥核心作用。总体而言，竞争态势强调互通性、品质保证以及提供端到端解决方案的能力，以减少临床和转化应用的障碍。

为产业领导者提供加速采用的可行建议，重点在于验证严谨性、以工作流程为中心的设计、供应链弹性、监管参与和资料协调

该领域的领导者应优先考虑一系列切实可行的措施，将创新转化为营运效益。首先，投资严格的检测验证途径，以解决分析性能、实验室间重现性和试剂可追溯性问题。这项基础性工作可以降低下游临床风险，并简化监管流程。自动化、使用者友善软体以及与实验室资讯系统的互通性将加速该技术在诊断和临床环境中的应用。第三，透过对多家供应商进行资格审查、探索区域製造伙伴关係伙伴关係以及维持关键试剂的策略性库存缓衝来增强供应链的韧性，以减轻贸易政策变化和物流限製造成的中断。

第四，儘早与临床和监管相关人员沟通，使验证计画与核准和报销预期保持一致。第五，与学术中心和合约研究组织 (CRO) 建立伙伴关係，以支持多中心验证研究并获得多样化的患者群体。第六，投资于数据协调和生物资讯学专业知识，以便从复杂的多组体学检测中获得临床可解释的结果。协调实施这些建议将提高新检测方法获得科学可信度并实用化为研究和临床实践的可能性。

透明的、专家主导的调查方法结合了相关人员访谈、技术综合和迭代专家评审，确保了可操作且可辩护的发现

本分析所采用的调查方法结合了主要相关人员访谈、二手文献整合和跨职能专家评审，以确保研究的严谨性和有效性。主要资讯包括对科研领导者、实验室主任和公司高管的访谈，他们就检测性能、部署挑战和应用驱动因素提供了第一手的观点。这些定性见解与技术文献和监管指南相互参考，从而基于当前的最佳实践和新兴标准得出结论。

分析方法着重于技术的比较评估、产品生命週期考量的评估以及基于情境的供应链和监管变数探索。特别关注可重复性基准、验证框架以及在学术、临床和商业性环境中的实施障碍。专家对研究结果进行反覆审核，以完善其策略意义，并将其转化为致力于检测方法开发、商业化和临床整合的相关人员的可行建议。

结论：技术进步、营运限制和策略要求的综合将决定哪些免疫肿瘤学检测将实现临床和商业性影响

总而言之，免疫肿瘤学检测正从最初的探索性套件包转变为一套临床相关、操作可扩展的解决方案，这些解决方案将对治疗方法开发和患者护理产生重大影响。多分析物检测、单细胞分析、定序深度和自动化技术的整合扩展了可测量和可解释的范围，而供应链现状和监管期望决定了检测的开发和部署方式。成功的策略将在技术目标与验证、可重复性和最终用户工作流程整合等实际考量之间取得平衡。

展望未来，那些投资于强大的检测验证、建立战略伙伴关係并设计出能够解决现实世界临床和实验室限制的解决方案的机构，将最有能力将科学进步转化为可衡量的临床和商业性价值。能够跨平台协调数据并将复杂的多维读数转化为具有临床意义的洞察，将成为该领域领导者的关键能力。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 整合高内涵成像分析，同时分析肿瘤微环境中的免疫细胞表型与功能
  • 开发基于液态生物检体的检测方法，用于非侵入性监测癌症患者免疫查核点抑制剂的疗效
  • 扩展多重细胞激素分析平台，以便即时详细评估免疫疗法诱导的生物标记
  • 单细胞定序分析在表征免疫治疗中的T细胞受体多样性和克隆性方面的进展
  • 标准化 PD-L1 IHC 检测与数位病理学相结合的商业化提高了预测准确性
  • 新兴的基于抗原的胜肽增殖检测方法，用于个人化癌症疫苗开发和患者选择
  • 在免疫检测中采用自动化和微射流来提高临床试验环境中的通量和可重复性
  • 针对新型免疫查核点标靶和组合的伴随诊断免疫检测的监管指南不断发展

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

8. 免疫肿瘤学检测市场（依技术类型划分）

  • 流式细胞技术
    • 常规流式细胞技术
    • 频谱流式细胞技术
  • 免疫检测
    • ELISA
    • 多重免疫检测
  • 质谱流式细胞仪
  • 次世代定序
    • 目标面板
    • 全EXOME定序
    • 全基因测序

9. 免疫肿瘤学检测市场（按产品）

  • 耗材
    • 探针和抗体
    • 试剂和套件
  • 装置
    • 自动化系统
    • 平台型设备

第 10 章。免疫肿瘤学检测市场（依样本类型）

  • 血
  • 细胞株
  • 组织

第 11 章。免疫肿瘤学检测市场（按最终用户）

  • 学术和研究机构
    • 研究所
    • 大学
  • 诊断实验室
  • 医院和诊所
  • 製药和生物技术

第 12 章：免疫肿瘤学检测市场（按适应症）

  • 乳癌
  • 血癌
  • 肺癌
  • 黑色素瘤

第十三章 免疫肿瘤学检测市场（依应用）

  • 生物标记发现
  • 伴随诊断
  • 细胞激素分析
  • 免疫监测
  • 肿瘤微环境分析

第 14 章。免疫肿瘤学检测市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第 15 章。免疫肿瘤学检测市场（按类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第 16 章：各国免疫肿瘤学检测市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Thermo Fisher Scientific Inc.
    • Danaher Corporation
    • Merck KGaA
    • Agilent Technologies, Inc.
    • Reaction Biology Corporation
    • Bio-Rad Laboratories, Inc.
    • Creative Biolabs
    • QIAGEN NV
    • Illumina, Inc.
    • Becton, Dickinson and Company
Product Code: MRR-43676CF42882

The Immuno Oncology Assays Market is projected to grow by USD 23.16 billion at a CAGR of 15.69% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 7.21 billion
Estimated Year [2025] USD 8.33 billion
Forecast Year [2032] USD 23.16 billion
CAGR (%) 15.69%

An authoritative introduction framing the strategic importance and scope of immuno-oncology assays across research, clinical development, and diagnostic use cases

The immuno-oncology assays landscape sits at the intersection of rapidly advancing biological understanding and increasingly sophisticated measurement technologies. This introduction frames the field's contemporary priorities: improving assay sensitivity and specificity, integrating multi-omic readouts, and translating laboratory discoveries into clinically actionable tools. It also establishes the report's remit to analyze technology evolution, product differentiation, sample handling considerations, end-user adoption patterns, and application-driven use cases that shape development and commercialization pathways.

This section underscores why immuno-oncology assays are central to modern oncology research and therapeutic development. From early-stage biomarker discovery through companion diagnostics and immune monitoring in clinical trials, assays serve as the backbone of objective decision-making. Throughout the report, emphasis is placed on reproducibility, regulatory alignment, and operational scalability as determinants of whether a technique moves from exploratory use to routine deployment. The introduction closes by outlining how subsequent sections will provide strategic context across technological, commercial, and regional dimensions to support investor, developer, and practitioner decision-making.

A synthesis of the transformative technological, regulatory, and commercial shifts reshaping assay development and accelerating adoption across translational and clinical settings

The past several years have witnessed transformative shifts that reconfigure both the scientific and commercial contours of immuno-oncology assays. Advances in single-cell resolution, multiplexed protein detection, and high-throughput sequencing have converged to expand the range of measurable immune phenotypes. At the same time, platforms that once served primarily as research tools are evolving toward clinical-grade implementations through improved automation, standardization, and quality control practices.

Concurrently, the ecosystem supporting assay deployment is changing; partnerships between instrument manufacturers, reagent suppliers, and contract research organizations are becoming more strategic and vertically integrated. This trend accelerates when assay workflows are designed with end-user constraints in mind, such as limits on sample volume, turnaround time pressures in clinical settings, and the need for interoperable data outputs. Regulatory expectations are also evolving, pushing developers to demonstrate analytical validity, clinical relevance, and robust quality management systems earlier in development. Together, these shifts create an environment where technological innovation must be matched by operational rigor and clear pathways to adoption if new assay modalities are to realize their potential in research and patient care.

How evolving tariff dynamics are prompting supply chain resilience, supplier diversification, and localization strategies for assay procurement and manufacturing

Trade policy changes and tariff adjustments have introduced additional layers of complexity for organizations operating global supply chains and deploying assays across clinical and research laboratories. Tariff dynamics influence sourcing strategies for instruments and consumables, affecting decisions about supplier diversification, regional inventory staging, and the localization of manufacturing capabilities. Many organizations now weigh the operational costs of cross-border procurement against the strategic value of maintaining access to specialized reagents and instruments that may be available only from a limited set of global suppliers.

In response, stakeholders are adopting a range of mitigations. Some are re-evaluating supplier agreements and entering into longer-term contracts to stabilize pricing and availability. Others are accelerating qualification procedures for alternative suppliers and investing in local manufacturing partners or contract manufacturers to reduce exposure to tariff-induced cost volatility. Additionally, procurement and supply chain teams are collaborating more closely with R&D and clinical operations to prioritize critical components and design assays that are less dependent on single-source inputs. These adaptations aim to preserve continuity of research and clinical programs while maintaining compliance and cost-effectiveness in the face of shifting trade policies.

Detailed segmentation insights revealing how technology platforms, product types, sample formats, end-user needs, indications, and applications interact to shape assay prioritization

Segment-level dynamics reveal where innovation, adoption, and commercial tension intersect across technology types, product categories, sample formats, end-user needs, indications, and applications. Within technology, established modalities such as flow cytometry coexist with mass cytometry and next-generation sequencing, each offering distinct strengths. Conventional flow cytometry remains a workhorse for phenotyping while spectral flow cytometry extends multiplexing capacity, and mass cytometry enables very high parameter profiling for deep immune phenotyping. Immunoassay formats continue to evolve from traditional ELISA toward multiplex immunoassays that deliver broader cytokine panels and higher throughput. Next-generation sequencing approaches span targeted panels tailored to immune-related loci, whole exome sequencing that provides broader genomic context, and whole genome sequencing for comprehensive analyses, with each tier balancing depth, breadth, and cost considerations.

Product segmentation differentiates consumables from instruments, where consumables encompass probes, antibodies, reagents, and kits that must be optimized for lot-to-lot consistency and assay specificity, and instruments include both automated systems that support high-throughput workflows and platform-based instruments designed for flexible use across multiple assay types. Sample type considerations influence workflow design and assay selection; blood-based assays offer minimally invasive longitudinal monitoring, cell line workstreams drive mechanistic discovery, and tissue-based assays provide spatial and contextual information critical for tumor microenvironment analysis. End users present varying priorities: academic and research institutes, including both research institutes and universities, prioritize assay flexibility and novel readouts, diagnostic laboratories emphasize regulatory compliance and throughput, hospitals and clinics require rapid turnaround and clinical utility, and pharmaceutical and biotech organizations focus on assay reproducibility and integration into clinical trial workflows. Indication-specific needs shape validation strategies and selection criteria; assays for breast cancer, hematologic cancers, lung cancer, and melanoma each confront distinct tissue availability, biomarker signatures, and clinical endpoints. Application-driven segmentation-biomarker discovery, companion diagnostics, cytokine analysis, immune monitoring, and tumor microenvironment analysis-dictates assay performance thresholds and data interpretation frameworks, informing whether an approach is most suitable for exploratory research, diagnostic development, or clinical trial readouts.

Taken together, these segment dimensions illustrate that successful assay strategies are those that align technology choice, product design, and operational execution with specific sample contexts, end-user workflows, and therapeutic indications. Transitional investments in assay standardization, cross-platform data harmonization, and user-centric automation bridge the gap between promising methods and widespread adoption.

Comparative regional insights illustrating how Americas, Europe Middle East & Africa, and Asia-Pacific market characteristics influence adoption, validation, and commercialization strategies

Regional characteristics exert strong influence on assay development priorities, commercialization strategies, and collaborative landscapes. In the Americas, academic-industry partnerships and a mature clinical trials infrastructure support rapid translation of novel assays into trial settings, while U.S. regulatory pathways and reimbursement dynamics guide the design and validation of companion diagnostics. Venture and corporate investment activity in this region often accelerates the scaling of platform technologies, and proximity to large clinical networks enables extensive clinical validation programs.

Europe, the Middle East & Africa exhibits a heterogeneous landscape where regulatory harmonization efforts, cross-border research collaborations, and national healthcare systems create both opportunities and complexities. European centers of excellence frequently lead multicenter studies focused on immune profiling and tumor microenvironment characterization, but developers must account for diverse regulatory expectations and reimbursement frameworks across jurisdictions. The Middle East and Africa are experiencing growing investments in research capacity and clinical infrastructure, creating nascent demand for robust, scalable assays that can be deployed in centralized laboratories.

Asia-Pacific is marked by rapidly expanding research output, increasing clinical trial activity, and an emphasis on local manufacturing and capacity building. Several countries are prioritizing biotech and life science initiatives, fostering ecosystems that support assay innovation and localized production of reagents and instruments. The region also presents opportunities for tailored diagnostic strategies that reflect population-specific disease biology and healthcare delivery models. Across all regions, cross-border collaborations and digital data sharing initiatives are helping to standardize methodologies and accelerate dissemination of best practices.

Key company-level dynamics showing how platform modularity, reagent quality, strategic partnerships, and service models are shaping competitive advantage and adoption pathways

Industry participants are forging differentiated positions through a combination of proprietary assay chemistries, integrated platforms, and service-oriented models. Leading instrument developers are investing in modular architectures that support multiple assay workflows, while reagent and consumable suppliers are concentrating on antibody validation, reagent stabilization, and lot-to-lot consistency to reduce variability in downstream data. Contract research organizations and specialized service providers are becoming strategic partners for organizations that lack in-house capacity to run large-scale immune monitoring or complex tissue-based assays, offering assay development, sample processing, and data analysis as bundled services.

Collaborations between diagnostics companies and pharmaceutical sponsors are increasingly common, driven by the need for companion diagnostics that can stratify patients and support therapeutic approval pathways. At the same time, smaller innovators are carving niches by delivering highly multiplexed assays, advanced single-cell analytics, or streamlined automation aimed at specific clinical workflows. Cross-sector partnerships, including academic spin-outs and instrument-reagent co-development agreements, are central to advancing assay robustness and accelerating clinical validation. Overall, competitive dynamics emphasize interoperability, quality assurance, and the ability to provide end-to-end solutions that reduce the barriers for clinical and translational adoption.

Actionable recommendations for industry leaders focusing on validation rigor, workflow-centric design, supply chain resilience, regulatory engagement, and data harmonization to accelerate adoption

Leaders in the field should prioritize a set of pragmatic, actionable measures to convert innovation into operational impact. First, invest in rigorous assay validation pathways that address analytical performance, reproducibility across sites, and traceability of reagents. This foundational work reduces downstream clinical risk and simplifies regulatory engagement. Second, design product and service offerings with the end-user workflow in mind: automation, user-friendly software, and interoperability with laboratory information systems accelerate adoption in diagnostic and clinical environments. Third, strengthen supply chain resilience by qualifying multiple suppliers, exploring regional manufacturing partnerships, and maintaining strategic inventory buffers for critical reagents to mitigate disruptions from trade policy changes and logistical constraints.

Fourth, engage early with clinical and regulatory stakeholders to align validation plans with approval and reimbursement expectations. Fifth, cultivate partnerships with academic centers and CROs to support multicenter validation studies and to access diverse patient cohorts. Sixth, invest in data harmonization and bioinformatics expertise to deliver clinically interpretable outputs from complex multi-omic assays. Implementing these recommendations in a coordinated fashion enhances the likelihood that new assays will achieve both scientific credibility and practical utility across research and clinical settings.

A transparent, expert-driven research methodology combining stakeholder interviews, technical synthesis, and iterative expert review to ensure actionable and defensible insights

The research methodology underpinning this analysis integrates primary stakeholder engagement, secondary literature synthesis, and cross-functional expert review to ensure rigor and relevance. Primary inputs include interviews with scientific leaders, laboratory directors, and commercial executives who bring firsthand perspectives on assay performance, deployment challenges, and adoption drivers. These qualitative insights are triangulated with technical literature and regulatory guidance to ground conclusions in current best practices and emerging standards.

Analytical approaches emphasize comparative technology assessment, evaluation of product lifecycle considerations, and scenario-based exploration of supply chain and regulatory variables. Special attention is paid to reproducibility benchmarks, validation frameworks, and implementation barriers across academic, clinical, and commercial settings. Findings were iteratively reviewed by subject-matter experts to refine strategic implications and to ensure that recommendations are actionable for stakeholders pursuing assay development, commercialization, or clinical integration.

Conclusion synthesizing technological progress, operational constraints, and strategic imperatives that determine which immuno-oncology assays will achieve clinical and commercial impact

In conclusion, immuno-oncology assays are transitioning from a predominantly exploratory toolkit toward a set of clinically relevant, operationally scalable solutions that can materially influence therapeutic development and patient care. The convergence of enhanced multiplexing, single-cell resolution, sequencing depth, and automation is expanding what is measurable and interpretable, while supply chain realities and regulatory expectations are shaping how assays are developed and deployed. Successful strategies will balance technological ambition with pragmatic considerations of validation, reproducibility, and end-user workflow integration.

Looking ahead, organizations that invest in robust assay validation, cultivate strategic partnerships, and design solutions that address real-world clinical and laboratory constraints will be best positioned to convert scientific advances into measurable clinical and commercial value. The ability to harmonize data across platforms and to translate complex multi-dimensional readouts into clinically meaningful insights will be the defining capability for leaders in this space.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of high-content imaging assays for simultaneous analysis of immune cell phenotypes and functions in tumor microenvironment
  • 5.2. Development of liquid biopsy-based assays for noninvasive monitoring of immune checkpoint inhibitor efficacy in cancer patients
  • 5.3. Expansion of multiplexed cytokine profiling platforms enabling detailed assessment of immunotherapy-induced biomarkers in real time
  • 5.4. Advancements in single-cell sequencing assays to characterize T-cell receptor diversity and clonality in response to immunotherapy
  • 5.5. Commercialization of standardized PD-L1 IHC assays with digital pathology integration for improved predictive accuracy
  • 5.6. Emergence of neoantigen-based peptide proliferation assays to personalize cancer vaccine development and patient selection
  • 5.7. Adoption of automation and microfluidics in immunoassays to increase throughput and reproducibility in clinical trial settings
  • 5.8. Regulatory guidelines evolution for companion diagnostic immunoassays aligning with novel immune checkpoint targets and combinations

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Immuno Oncology Assays Market, by Technology Type

  • 8.1. Flow Cytometry
    • 8.1.1. Conventional Flow Cytometry
    • 8.1.2. Spectral Flow Cytometry
  • 8.2. Immunoassay
    • 8.2.1. Elisa
    • 8.2.2. Multiplex Immunoassay
  • 8.3. Mass Cytometry
  • 8.4. Next Generation Sequencing
    • 8.4.1. Targeted Panel
    • 8.4.2. Whole Exome Sequencing
    • 8.4.3. Whole Genome Sequencing

9. Immuno Oncology Assays Market, by Product

  • 9.1. Consumables
    • 9.1.1. Probes And Antibodies
    • 9.1.2. Reagents And Kits
  • 9.2. Instruments
    • 9.2.1. Automated Systems
    • 9.2.2. Platform Based Instruments

10. Immuno Oncology Assays Market, by Sample Type

  • 10.1. Blood
  • 10.2. Cell Lines
  • 10.3. Tissue

11. Immuno Oncology Assays Market, by End User

  • 11.1. Academic And Research Institutes
    • 11.1.1. Research Institutes
    • 11.1.2. Universities
  • 11.2. Diagnostic Laboratories
  • 11.3. Hospitals And Clinics
  • 11.4. Pharmaceutical And Biotech

12. Immuno Oncology Assays Market, by Indication

  • 12.1. Breast Cancer
  • 12.2. Hematologic Cancers
  • 12.3. Lung Cancer
  • 12.4. Melanoma

13. Immuno Oncology Assays Market, by Application

  • 13.1. Biomarker Discovery
  • 13.2. Companion Diagnostics
  • 13.3. Cytokine Analysis
  • 13.4. Immune Monitoring
  • 13.5. Tumor Microenvironment Analysis

14. Immuno Oncology Assays Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Immuno Oncology Assays Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Immuno Oncology Assays Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Thermo Fisher Scientific Inc.
    • 17.3.2. Danaher Corporation
    • 17.3.3. Merck KGaA
    • 17.3.4. Agilent Technologies, Inc.
    • 17.3.5. Reaction Biology Corporation
    • 17.3.6. Bio-Rad Laboratories, Inc.
    • 17.3.7. Creative Biolabs
    • 17.3.8. QIAGEN N.V.
    • 17.3.9. Illumina, Inc.
    • 17.3.10. Becton, Dickinson and Company

LIST OF FIGURES

  • FIGURE 1. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. IMMUNO ONCOLOGY ASSAYS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. IMMUNO ONCOLOGY ASSAYS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. IMMUNO ONCOLOGY ASSAYS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY FLOW CYTOMETRY, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY FLOW CYTOMETRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY FLOW CYTOMETRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY FLOW CYTOMETRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY FLOW CYTOMETRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CONVENTIONAL FLOW CYTOMETRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CONVENTIONAL FLOW CYTOMETRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CONVENTIONAL FLOW CYTOMETRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CONVENTIONAL FLOW CYTOMETRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CONVENTIONAL FLOW CYTOMETRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CONVENTIONAL FLOW CYTOMETRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY SPECTRAL FLOW CYTOMETRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY SPECTRAL FLOW CYTOMETRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY SPECTRAL FLOW CYTOMETRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY SPECTRAL FLOW CYTOMETRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY SPECTRAL FLOW CYTOMETRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY SPECTRAL FLOW CYTOMETRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY ELISA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY ELISA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY ELISA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY ELISA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY ELISA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY ELISA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY MULTIPLEX IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY MULTIPLEX IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY MULTIPLEX IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY MULTIPLEX IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY MULTIPLEX IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY MULTIPLEX IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY MASS CYTOMETRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY MASS CYTOMETRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY MASS CYTOMETRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY MASS CYTOMETRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY MASS CYTOMETRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY MASS CYTOMETRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TARGETED PANEL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TARGETED PANEL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TARGETED PANEL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TARGETED PANEL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TARGETED PANEL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TARGETED PANEL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CONSUMABLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CONSUMABLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CONSUMABLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PROBES AND ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PROBES AND ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PROBES AND ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PROBES AND ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PROBES AND ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PROBES AND ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY REAGENTS AND KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY REAGENTS AND KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY REAGENTS AND KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY REAGENTS AND KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY REAGENTS AND KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY REAGENTS AND KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY AUTOMATED SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY AUTOMATED SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY AUTOMATED SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY AUTOMATED SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY AUTOMATED SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY AUTOMATED SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PLATFORM BASED INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PLATFORM BASED INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PLATFORM BASED INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PLATFORM BASED INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PLATFORM BASED INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PLATFORM BASED INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY BLOOD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY BLOOD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY BLOOD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY BLOOD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY BLOOD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY BLOOD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CELL LINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CELL LINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CELL LINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CELL LINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CELL LINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CELL LINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TISSUE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TISSUE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TISSUE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TISSUE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TISSUE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TISSUE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY UNIVERSITIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY UNIVERSITIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY UNIVERSITIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY UNIVERSITIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY UNIVERSITIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY UNIVERSITIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY HEMATOLOGIC CANCERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY HEMATOLOGIC CANCERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY HEMATOLOGIC CANCERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY HEMATOLOGIC CANCERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY HEMATOLOGIC CANCERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY HEMATOLOGIC CANCERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY LUNG CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY MELANOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY MELANOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY MELANOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY MELANOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY MELANOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY MELANOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY BIOMARKER DISCOVERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY BIOMARKER DISCOVERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY BIOMARKER DISCOVERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY BIOMARKER DISCOVERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CYTOKINE ANALYSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CYTOKINE ANALYSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CYTOKINE ANALYSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CYTOKINE ANALYSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CYTOKINE ANALYSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CYTOKINE ANALYSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY IMMUNE MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY IMMUNE MONITORING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY IMMUNE MONITORING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY IMMUNE MONITORING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY IMMUNE MONITORING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY IMMUNE MONITORING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TUMOR MICROENVIRONMENT ANALYSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TUMOR MICROENVIRONMENT ANALYSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TUMOR MICROENVIRONMENT ANALYSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TUMOR MICROENVIRONMENT ANALYSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TUMOR MICROENVIRONMENT ANALYSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TUMOR MICROENVIRONMENT ANALYSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 241. AMERICAS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 242. AMERICAS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 243. AMERICAS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 244. AMERICAS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 245. AMERICAS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2024 (USD MILLION)
  • TABLE 246. AMERICAS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY FLOW CYTOMETRY, 2025-2032 (USD MILLION)
  • TABLE 247. AMERICAS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 248. AMERICAS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 249. AMERICAS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 250. AMERICAS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 251. AMERICAS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 252. AMERICAS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 253. AMERICAS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 254. AMERICAS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 255. AMERICAS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 256. AMERICAS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 257. AMERICAS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. AMERICAS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 259. AMERICAS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 260. AMERICAS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 261. AMERICAS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
  • TABLE 262. AMERICAS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2025-2032 (USD MILLION)
  • TABLE 263. AMERICAS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 264. AMERICAS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 265. AMERICAS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 266. AMERICAS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 267. NORTH AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 268. NORTH AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 269. NORTH AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 270. NORTH AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 271. NORTH AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2024 (USD MILLION)
  • TABLE 272. NORTH AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY FLOW CYTOMETRY, 2025-2032 (USD MILLION)
  • TABLE 273. NORTH AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 274. NORTH AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 275. NORTH AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 276. NORTH AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 277. NORTH AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 278. NORTH AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 279. NORTH AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 280. NORTH AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 281. NORTH AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 282. NORTH AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 283. NORTH AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 284. NORTH AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 285. NORTH AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 286. NORTH AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 287. NORTH AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
  • TABLE 288. NORTH AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2025-2032 (USD MILLION)
  • TABLE 289. NORTH AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 290. NORTH AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 291. NORTH AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 292. NORTH AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 293. LATIN AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 294. LATIN AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 295. LATIN AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 296. LATIN AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 297. LATIN AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2024 (USD MILLION)
  • TABLE 298. LATIN AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY FLOW CYTOMETRY, 2025-2032 (USD MILLION)
  • TABLE 299. LATIN AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 300. LATIN AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 301. LATIN AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 302. LATIN AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 303. LATIN AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 304. LATIN AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 305. LATIN AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 306. LATIN AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CONSUMABLES, 2025-